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Tbjective: The main advantage of bioprostheses, avoidance of anticoagulant ther-
py, is compromised during the early postoperative period; in fact, warfarin is often
dministered during the first 3 postoperative months.
ethods: We analyzed 250 patients undergoing tissue aortic valve replacement
etween January 2002 and December 2005. The patients received either aspirin
group 1) or oral anticoagulation (group 2) during the first 3 months. In a subgroup
f these patients, we investigated the possible presence of clinically silent micro-
mbolization by means of transcranial Doppler for microembolic signal detection.
esults: Thirty-day mortality was 0%. No major neurologic events occurred. Two
pisodes of bleeding were observed in both groups. Follow-up time was 24  14
onths. Overall late mortality rate was 0.8% in group 1 versus 12% (mainly cancer
elated) in group 2. In group 2, 2 deaths were due to major ischemic neurologic
vents; overall, 3 major neurologic episodes occurred (international normalized
atio was within therapeutic range). There were no neurologic events in group 1 (P
.12). Stroke-free survival did not reach statistical significance between the 2
roups. Transcranial Doppler was performed after a mean interval of 55  19 days,
ith no detection of microembolic signals in patients receiving either aspirin or
arfarin. There were no episodes of bleeding or neurologic events.
onclusions: Aspirin therapy appears to be the appropriate response to both cardiac
urgeons’ and patients’ needs in the early postoperative course after aortic valve
eplacement with tissue valves, demonstrating adequate antithromboembolic effi-
acy with no added risk for bleeding as well as ease of administration.
n the first 3 postoperative months after biologic valve replacement, patients are
recognized to be at higher risk for thromboembolic events, therefore requiring
antithrombotic prophylaxis.1 According to the American College of Cardiolo
ACC)/American Heart Association (AHA) guidelines, antithrombotic therapy
hould be administered during this time frame until the exposed components of the
ioprosthesis are fully endothelialized. In the previous edition (1998), warfarin was
ecommended during the first 3 postoperative months after biologic valve replace-
ent (class I).2 In the most recent edition (2006), aspirin is indicated at 75 
g per day after biologic valve replacement in patients with no risk factors (class
, level of evidence C), and warfarin therapy (international normalized ratio [INR]
.5-3.5) is suggested as a class IIa recommendation (level C).3
Since the 1980s, cardiac surgeons have been practicing policies different from
arfarin, mainly based on antiplatelet agents, which offer the advantages of an
asier administration modality as well as a reduced risk for postoperative bleeding
hen compared with warfarin. However, we believe that evidence-based clinical
nd instrumental data are mandatory to provide additional information. With the aim
o evaluate the clinical impact of the antithrombotic therapy in patients receiving
he Journal of Thoracic and Cardiovascular Surgery ● Volume 133, Number 6 1597
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1
CSPortic bioprostheses and to provide instrumental data sup-
orting either strategy, we analyzed 250 consecutive pa-
ients undergoing tissue aortic valve replacement at our
nstitution (single-center study) between January 2002 and
ecember 2005; the patients received either oral anticoag-
lation or aspirin as antithrombotic prophylaxis during the
rst 3 postoperative months. Additionally, in a subgroup of
hese patients, we investigated the possible presence of
linically silent microembolization by means of transcranial
oppler (TCD) for microembolic signal (MES) detection.
herefore, this study provides both clinical and instrumental
ata supporting the evidence that antiplatelet therapy alone
s safe and effective for patients receiving aortic
ioprostheses.
aterials and Methods
atients
he study population consisted of 250 patients divided into 2 arms.
he first arm included 200 consecutive patients (103 men, 97
omen; mean age 76  4 years) who underwent bioprosthetic
ortic valve replacement (BAVR) at our institution between Jan-
ary 2002 and September 2005. Patients were divided into 2
roups according to the postoperative antithrombotic regimen.
ccording to the operating surgeon’s preference, patients were
reated either with warfarin (target INR 2-3; 100 patients) or
spirin (100 mg/d; 100 patients). All patients were prospectively
ntered into the study. The patient data were prospectively col-
ected at the time of the operation, and patients were prospectively
ollowed by both ambulatory clinical evaluations and phone inter-
iews at repeated intervals. The second arm included 50 consec-
tive patients (25 men, 25 women; mean age 75  5 years)
perated on between April and October 2005. These 50 patients,
ho received an aortic valve bioprosthesis, were randomly as-
igned to receive either antiplatelet therapy (group APMES: 25
atients) or oral anticoagulation (group ACMES: 25 patients)
uring the first 3 postoperative months. The patients were prospec-
ively entered into the study and preoperative, operative, and
ostoperative data were prospectively collected. Follow-up ambu-
atory clinical evaluations were planned. These patients were also
onitored by TCD for MES detection before discharge and within
he first 3 postoperative months.
According to the exclusion criteria, all patients affected by
omorbidities requiring chronic antithrombotic therapy and who
Abbreviations and Acronyms
ACC  American College of Cardiology
AHA  American Heart Association
BAVR bioprosthetic aortic valve replacement
CABG coronary artery bypass graft
CPB  cardiopulmonary bypass
INR  international nationalized ratio
MES microembolic signal
TCD  transcranial Dopplerere receiving preoperative warfarin were excluded from the i
598 The Journal of Thoracic and Cardiovascular Surgery ● Juntudy. Also, patients receiving concomitant mitral/tricuspid valve
eplacement were excluded from the study. Demographic data of
he overall patient population as well as specific data of patients
ABLE 1. Demographic data
Group 1,
n  125
(%)
Group 2,
n  125
(%) P
ex .75
Male 67 (53) 65 (52)
Female 58 (46) 60 (48)
ge (y) 75 6 75  5 .5
ypertension 65 (52) 57 (46) .28
iabetes 27 (22) 28 (22) .97
yslipidemia 37 (30) 29 (23) .21
eripheral artery disease 26 (21) 17 (14) .1
arotid artery stenosis (50%) 10 (8) 17 (14) .15
oronary artery disease 33 (26) 33 (26)
rior cerebrovascular
accidents
8 (6) 14 (11) .18
trial fibrillation (previous atrial
fibrillation, now sinus
rhythm)
7 (6) 10 (8) .45
edo 3 (2) 6 (5) .31
APMES,
n  25
(%)
ACMES,
n  25
(%) P
ex .32
Male 16 (64) 13 (52)
Female 9 (36) 12 (48)
ge (y) 75 5 75  5 .86
moking history 8 (32) 12 (48) .32
ypertension 20 (80) 23 (92) .24
iabetes 4 (16) 8 (32) .27
yslipidemia 10 (40) 19 (76) .01
eripheral artery disease 3 (12) 3 (12) .67
arotid artery stenosis (50%) 7 (28) 7 (28) .9
arotid artery stenosis (50%) 4 (16) 2 (8) .17
rior cerebrovascular event 4 (16) 3 (12) .73
trial fibrillation 2 (8) 7 (28) .15
edo 1 (4) 1 (4) .98
rior acute myocardial
infarction
0 2 (8) .14
oronary artery disease
75% 4 (16) 5 (20) .66
75% 2 (8) 6 (24) .11
ortic valve disease
Aortic stenosis 19 (76) 20 (80) .57
Aortic insufficiency 3 (12) 1 (4) .32
Mixed disease 3 (12) 4 (16) .64
VEF (%) 56 11 57 12 .85
VEDV (mL/m2) 73  24 61 12 .04
VEF, Left ventricle ejection fraction; LVEDV, left ventricle end-diastolic
olume.nvestigated for MES detection are listed in Table 1.
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CS
PThe outcome variables were defined according to the guidelines
or reporting morbidity and mortalitity after cardiac valvular
perations.4
urgical Technique
perations were performed through median sternotomy, by car-
iopulmonary bypass (CPB), with moderate hypothermia, and
ith aortic crossclamp. Myocardial ischemic arrest was achieved
ith cold blood cardioplegic solution, either antegrade and retro-
rade, administered at 20-minute intervals. The aortic bioprosthe-
is was implanted through a transaortic approach, using multiple
nterrupted noneverted 2-0 Ticron (Ethicon, Somerville, NJ) su-
ures, reinforced with Teflon (Boston Scientific, Natick, Mass)
ledgets.
ntithrombotic Therapy
ow-molecular-weight heparin was routinely administered starting
rom the first postoperative day in the absence of significant blood
oss from drainage tubes. Oral antithrombotic prophylaxis was
tarted on the second postoperative day. One hundred twenty-five
atients received aspirin (100 mg/d; group 1), and 125 patients
ere treated with warfarin (group 2), maintaining a target INR of
to 3 (group AC). Subcutaneous heparin was discontinued once
atients were fully mobilized (group 1) or target INR was reached
group 2).
atient Follow-up
ll patients were prospectively followed. The patients were peri-
dically visited at our outpatient clinic plus contacted by phone for
linical interviews at repeated intervals. The anticoagulant/antiag-
regant therapy assumed was ascertained, and INR was monitored
n all anticoagulated patients. New York Heart Association class
as adopted to score patients’ clinical status. Additionally, in 50
atients (second study arm), 30-minute TCD by a multifrequency
oppler instrumentation (EmboDop, DWL, Singen, Germany)
hrough transtemporal window was performed for MES detection.
ll TCDs were carried out and analyzed by a single neurologist
ithin the first 3 postoperative months.
tatistical Analysis
ifferences among the patients of the 2 groups were tested with
tudent t test for independent samples for normally distributed
ariables, and 2 test was used to evaluate nominal qualitative
ariables. Analysis of variance for repeated measures was used to
est the significance of side and group. Statistics were performed
y means of the STATISTICA 6 package (Statsoft Inc,
984-2004).
esults
perative Results
he overall operative data of the 250 patients are reported in
able 2, including specific data regarding the 50 pat
ho underwent MES investigation. All patients received a
tented bioprosthesis: 128 Carpentier–Edwards Perimount
Edwards Lifesciences, Irvine, Calif) pericardial valves (50
n group 1 vs 78 in group 2) and 122 St Jude Biocor/Epic (St
ude Medical, Inc, St Paul, Minn) porcine bioprostheses (75 i
The Journal of Thoracicn group 1 vs 47 in group 2). Associated procedures were
erformed in 34% of group 1 patients versus 42% of group
patients (P  .44), mainly consisting of coronary artery
ypass graft (CABG). There were no significant differences
ither in CPB or crossclamp time between the 2 groups.
ostoperative Data
he postoperative outcome of the overall population is
eported in Table 3. In the entire series, 30-day mor
as 0%. No major neurologic events occurred. According
o postoperative bleeding, 2 episodes were observed among
ntiaggregated patients (specifically APMES patients) in 2
atients who underwent concomitant CABG and required
rainage procedures (1 pericardiocentesis and 1 thoracente-
is). Two major bleeding episodes also occurred in the
nticoagulated cohort.
Specific postoperative data regarding the group of
atients investigated with TCD are also shown: mean
ABLE 2. Operative data
Group 1
n  125
(%)
Group 2
n  125
(%) P
solated BAVR 73 (58) 82 (66)
AVR  other surgical procedures 52 (42) 43 (34) .44
AVR  CABG 35 34
AVR  ascending aorta
replacement
8 4
AVR  carotid TEA 5 4
ther 4 1
ortic bioprosthesis implanted
Carpentier–Edwards 50 (40) 78 (62)
Perimount
iocor/Epic 75 (60) 47 (38)
APMES
n  25
(%)
ACMES
n  25
(%) P
ody surface area (m2) 1.8  0.1 2 0,2 .85
VR 12 (48) 14 (56)
VR  associated procedures 13 (52) 11 (44) .57
VR  coronary artery bypass grafting 6 6
VR  ascending aorta replacement 3 2
VR  ascending aorta replacement
 carotid TEA
1 0
thers 3 3
ortic crossclamp time (min) 103 34 101  30 .72
ardiopulmonary bypass (min) 144 60 134  36 .72
ortic bioprosthesis implanted
Carpentier Edwards Perimount 7 (28%) 10 (40%) .37
St Jude Biocor/Epic 18 (72%) 15 (60%) .37
AVR, Bioprosthetic aortic valve replacement; CABG, coronary artery
ypass graft; TEA, thromboendarterectomy; AVR, aortic valve replacement.ntensive care unit stay was 1  1 days in patients taking
and Cardiovascular Surgery ● Volume 133, Number 6 1599
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1
CSPspirin versus 1  1 days in anticoagulated patients;
ean length of mechanical ventilation (9  3 hours in
roup APMES vs 10  5 hours in ACMES; P  .9) was
ot different between the 2 groups, as well as total
ospitalization time (9  4 days in group APMES vs 7 
days in group ACMES; P  .6). Echocardiographic
ata regarding postoperative left ventricular volume and
unction were superimposable.
ollow-up Data
ollow-up was 100% complete. Follow-up time was 24 
4 months (median time 20 months; range 2–47 months).
verall late mortality rate was 0.8% (1 of 125 patients,
ancer-related death) among patients treated with aspirin
ersus 12% (15 of 125 patients, mainly cancer-related
eaths) (P  .0003) in anticoagulated patients. Among
nticoagulated patients, 2 deaths were due to major isch-
mic neurologic events; overall, 3 major neurologic epi-
odes occurred (INR was within therapeutic range). There
ere no neurologic events in patients taking aspirin (P 
12). There were no late deaths in the warfarin group due to
leeding. Cancer-related deaths were secondary to impov-
rished global physical conditions. Stroke-free survival did
ot reach statistical significance between the 2 groups (
re 1).
According to the instrumental follow-up, TCD evalua-
ion was performed after a mean time interval of 55  19
ays (median time 51 days, range 10-90 days) after the
peration. No MES signals were detected during a 30-
inute TCD bilateral examination in either APMES or
ABLE 3. Postoperative data
Group 1
n  125
(%)
Group 2
n  125
(%) P
erioperative (30-d) death 0 0
ajor neurologic events within
30 postoperative days*
0 0
ajor bleeding within 30
postoperative days*
2 (1.6%) 2 (1.6%)
APMES
n  25
ACMES
n  25 P
ntensive care unit stay (d) 1 1 1  1
echanical ventilation length (h) 9 3 10 5 .90
otal postoperative stay (d) 9 4 9  3 .96
VEF, (%) 57 5 55 7 .33
VEDV, (mL/m2) 61  15 63  17 .66
ajor neurologic events* 0 0
ajor bleeding* 2 (8) 0
After starting anticoagulation/antiaggregation therapy. LVEF, Left ventri-
le ejection fraction; LVEDV, left ventricle end-diastolic volume.CMES group. No patient presented with either minor or (
600 The Journal of Thoracic and Cardiovascular Surgery ● Junajor neurologic events in either group, and there were no
ostoperative bleeding episodes.
Overall follow-up data are reported in Table 4 as w
ollow up data specifically regarding patients investigated
or MES detection (TCD data are also listed).
iscussion
ccording to the established guidelines on antithrombotic
rophylaxis after valve replacement, oral anticoagulation
herapy is required for a limited time after implantation of
iologic heart valve prostheses. The ACC/AHA task force
ecommended warfarin administration with a target INR of
.5 to 3.5 during the first postoperative months (class I);
ater, in absence of risk factors for thromboembolism, long-
erm therapy with aspirin (80-100 mg/d) is suggested.2 In
he most recent guidelines’ edition (2006), aspirin is indi-
ated at 75 to 100 mg per day after biologic valve replace-
ent in patients with no risk factors (class I, level of
vidence C), and warfarin therapy (INR 2.5-3.5) is sug-
ested as a class IIa recommendation (level C).3
In the first 3 postoperative months, patients are currently
ecognized to be at higher risk for thromboembolic events;
uch risk decreases once the endothelialization process of
tent and sutures has been completed. Early oral anticoag-
lation has been advocated also by the fifth American
ollege of Chest Physicians consensus conference on anti-
hrombotic therapy, according to site of insertion: a grade
1 recommendation is indicated for mitral prostheses, al-
hough the evidence for aortic valves is less compelling
C2). Nevertheless, during the first 3 postoperative months,
 target INR of 2.5 was indicated (class A1).5 More re-
ently, the seventh American College of Chest Physicians
onference recommended either vitamin K antagonists
Figure 1. Stroke-free survival.grade 2C) or aspirin (grade 1C) as antithrombotic prophy-
e 2007
l
i
p
s
m
t
c
w
c
r
r
L
w
a
t
r
A
m
a
c
r
a
t
c
s k
i
a
m
p
B
f
C
e
fi e
m
i
B
i
a
a
t
3
e
e
B
p
a
a s
c
w
(
t
r
o
t
r
d
B
a
w
p
w
o
T
D
C
N
M
M
D
M
M
T
R
R
R
R
L
L
L
L
*
c
D
di Marco et al Cardiopulmonary Support and Physiology
CS
Paxis during the first 3 months after aortic bioprosthetic
mplant.6
Currently, the vast majority of patients receiving a bio-
rosthesis are elderly patients, who frequently present with
ignificant comorbidities and have physiologically reduced
ultiorgan function due to senescence. These patients are
herefore prone to possible anticoagulation-related compli-
ations, compared with younger patients. Elderly patients
ould therefore benefit from complete freedom from anti-
oagulant therapy beginning in the early postoperative pe-
iod. Besides, during the first few days, oral anticoagulation
equires strict INR monitoring by repeated blood sampling.
ater, INR monitoring controls may be deferred, but still
arfarin action is jeopardized by drug interactions as well
s food interactions.7 Furthermore, excessive anticoagula-
ion related to warfarin narrow therapeutic index might be
esponsible for bleeding events in the postoperative period.
ABLE 4. Follow-up data
Group 1
n  125
(%)
Group 2
n  125
(%) P
eath 1 (0.8%) 15 (12%) .0003
ause of death:
Neoplasia 1 5
Heart failure 0 1
AMI 0 1
Endocarditis 0 1
Cerebral ischemia 0 2 .12
Other 0 5
YHA (III-IV)at follow-up 2 (1.6%) 6 (4.8%)
ajor neurologic events after 30
postoperative days*
0 3 (2.4%) .12
ajor bleeding after 30
postoperative days*
0 0
APMES
n  25
ACMES
n  25 P
eath at follow-up 0 0
ajor neurologic events 0 0
ajor bleeding events 0 0
CD parameters
ight medium velocity 49 12 64 18 .001
ight pulsation index 1 0.2 1 0.2 .66
ight depth 1 1 1  0.2 .68
ight MES 0 0
eft medium velocity 51 15 61 1 .05
eft pulsation index 1 0.2 1 0.2 .54
eft depth 55 2 55 1 .76
eft MES 0 0
After starting anticoagulation/antiaggregation therapy. AMI, acute myo-
ardial infarction; NYHA, New York Heart Association; TCD, transcranial
oppler; MES, microembolic signal.ntiplatelet therapy, which does not require either assess- T
The Journal of Thoracicent of therapeutic plasma levels or progressive dosage
djustment, bears evident advantages in terms of patient
ompliance and comfort. Above all, it would reduce the
isks of postoperative bleeding related to excessive
nticoagulation.
Since the 1980s, several reports have proposed alterna-
ive policies, mainly based on antiplatelet drugs, which have
learly become a reliable alternative to warfarin for cardiac
urgeons.8 Unfortunately, most published reports are lac-
ng in a prospective randomized approach, which does not
dequately strengthen the data with definite evidence.
Despite the absence of evidence-supporting data, in
any centers aspirin has currently replaced warfarin as the
ostoperative antithrombotic treatment of choice after
AVR, as evidenced by a recent CTSNet on-line report. In
act, this survey clearly outlines that the current practice of
TSNet surgeons, even if mostly aware of guidelines, un-
xpectedly diverge from them.9 This diverging trend, con-
rmed by the Euro Heart Survey Study,10 is a reliabl
irror of the current practice in many centers, including our
nstitution, where the policy of aspirin administration after
AVR has been adopted in recent years.
More recent work has prospectively compared the clin-
cal outcome of patients undergoing BAVR and treated with
nticoagulant regimens or antiplatelet therapies. Gherli and
ssociates prospectively investigated 249 consecutive pa-
ients who received either warfarin or aspirin during the first
months after BAVR. No statistically significant differ-
nces were reported in terms of cerebral ischemic events or
arly bleeding.11
In a retrospective analysis on 1150 patients undergoing
AVR, there was no advantage in terms of embolic stroke
rotection in anticoagulated patients (intravenous heparin
nd warfarin) versus patients assuming either aspirin or no
ntithrombotic therapy at all.12 Aramendi and coworker
onducted a prospective multicenter randomized trial in
hich 199 patients were randomized to antiaggregation
trifusal) or anticoagulation (acenocumarol) after biopros-
hetic implant (aortic, mitral, or mitroaortic) with similar
esults.13
After these encouraging results in terms of neurologic
utcome, which seem to support the adoption of antiplatelet
herapies, especially aspirin, in the early postoperative pe-
iod after aortic valve replacement with bioprostheses, we
ecided to prospectively evaluate our patients undergoing
AVR and to compare clinical outcome in patients who,
ccording to operating surgeon’s preference, received either
arfarin or aspirin as antithrombotic regimen in the first 3
ostoperative months. Operative and postoperative results
ere comparable. Mean ventilation time and length of post-
perative stay were similar, as well as bleeding episodes.
here were no neurologic complications.
and Cardiovascular Surgery ● Volume 133, Number 6 1601
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1
CSPBecause we are convinced that a negative clinical neu-
ologic evaluation cannot exclude the possibility of a silent
icroembolization, in a subgroup of 50 patients we decided
o strengthen the clinical investigation with instrumental
ata acquired by TCD examination for MES identification.
n fact, in a preliminary study on MES occurrence in pros-
hetic valve recipients,14 we could identify a correspo-
ence between the absence of MES signals in patients
reated with aspirin instead of warfarin after BAVR and
neventful clinical outcome (0% of neurologic complica-
ions and 0% MES detection). Moreover, we believe that
nstrumental-based evidence would be necessary to confirm
linical observation and support cardiac surgeons in adopt-
ng alternative therapeutic policies.
TCD has recently been proposed for neurologic moni-
oring after cardiac surgery.15 In fact, MESs have be
dentified both intraoperatively and postoperatively in pa-
ients undergoing cardiac surgery on CPB.16 Doppler sig-
als that have been interpreted as microbubbles have been
elated with postoperative neuropsychologic deficits17 and
lteration of working memory.18 In the early 1990s, Dop-
er signals were detected in patients with prosthetic
alves.19 In particular, MESs have been recorded in -
hanical valve recipients, and an increased MES frequency
as been observed in patients presenting with cerebrovas-
ular events compared with asymptomatic patients.20 The
pparent lack of correlation between MES count and anti-
oagulation regimen and level, as evidenced by others,21 is
ompatible with a gaseous nature of MES; high-pressure
radients at mechanical valve closure generate cavitation-
ike phenomena that would be responsible for the creation
f microbubbles from dissolved blood gases. Rarely, MES
ignals have also been seen in patients with biologic
alves,22,23 but the pathogenetic mechanism is still 
bject of debate. In the latter case, the different transvalvu-
ar flow pattern, with lesser gradients generating at valve
losure, is not compatible with the above-mentioned cavi-
ation phenomena, and a different pathogenesis should be
ddressed. According to a more reliable hypothesis, the
igh-intensity echoes identified in bioprosthetic valve recip-
ents would be in favor of particulated microaggregates,
uch as platelets or fibrin microparticles, whose formation
ight be due to interaction between blood elements and
alve components.22
Nevertheless, the reported information in the literature
bout MES prevalence in biologic valve recipients is sparse;
onflicting results on correlation between MES count and
revalence of neurologic adverse events mainly refer to
echanical prostheses, in which a different MES generation
echanism is involved. We believe that in tissue valves,
CD evaluation could contribute to overcome a potential
nderestimation of sheer clinical evaluation (whereas MES
dentification probably correlates to the presence of micro-
602 The Journal of Thoracic and Cardiovascular Surgery ● Junhrombotic aggregates). In fact, microembolization, even
ontinuous, might be silent at clinical neurologic evaluation.
CD might add further useful information to clinics with a
oninvasive, contrast-free examination and no need for pa-
ient exposure to X-rays. The absence of MES at a trans-
ranial evaluation might strengthen the value of neurologic
ilence at clinical evaluation. With this aim and to further
onfirm our previous observations,14,24 we performed addi-
ional instrumental evaluation in 50 patients (25 patients
eceiving aspirin and 25 patients receiving warfarin), and
e did not observe any MES signals in either group.
The clinical and instrumental results of this study con-
rmed aspirin therapy to be as effective as warfarin in
rotecting patients with biologic aortic valves from throm-
oembolic episodes in the early postoperative period. In
act, no neurologic events occurred during the postoperative
ourse, and no signal of microembolization was evident at
he TCD evaluation.
Aspirin administration was also associated with optimal
atient compliance for the ease of administration and for the
ack of need of INR continuous monitoring, with evident
dvantages in terms of postoperative quality of life. Aspirin
herapy in fact completely responds to postoperative expec-
ations, because patients’ disappointment toward even time-
imited anticoagulation therapy is not infrequent after
eceiving tissue valve implant. However, aspirin adminis-
ration in some cases carries the risk of ineffective throm-
oembolic protection due to aspirin resistance; nevertheless,
iochemical tests to disclose this treacherous eventuality are
urrently available.25
The study has some limitations. In fact, the randomiza-
ion methods (especially in group 1) might imply some bias,
nd the TCD evaluation, which was chosen because it is
oninvasive, is repeatable, and does not require exposure to
-rays, has some intrinsic limits. Furthermore, more defin-
tive information would require the evaluation of a larger
ohort of patients.
Nevertheless, aspirin therapy appears to respond appro-
riately to both cardiac surgeons’ and patients’ needs in the
arly postoperative course after aortic valve replacement
ith tissue valves, evidencing adequate antithromboem-
olic efficacy with no added risk for bleeding as well as ease
f administration.
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